WAM
CLVS

Wealthspire Advisors (Maryland)’s Clovis Oncology, Inc. CLVS Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-215
Closed -$5K – 2259
2019
Q1 		$5K Buy
+215
New +$5.39K ﹤0.01% 1861

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CLVS Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 215 shares — an estimated $5K sold.

Wealthspire Advisors (Maryland) first reported a position in CLVS in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 215 Clovis Oncology, Inc. shares in Q2 2019, an estimated $5K.
  • Wealthspire Advisors (Maryland) first reported a position in Clovis Oncology, Inc. in Q1 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Clovis Oncology, Inc. position peaked at $5K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.